219 related articles for article (PubMed ID: 23963796)
21. Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.
Shen X; Denittis A; Werner-Wasik M; Axelrod R; Gilman P; Meyer T; Treat J; Curran WJ; Machtay M
Radiat Oncol; 2011 Feb; 6():17. PubMed ID: 21324160
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer.
Tamiya A; Tamiya M; Shiroyama T; Kanazu M; Hirooka A; Tsuji T; Morishita N; Asami K; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Hirashima T; Atagi S; Kawase I
Ann Oncol; 2013 Apr; 24(4):980-5. PubMed ID: 23136232
[TBL] [Abstract][Full Text] [Related]
23. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
[TBL] [Abstract][Full Text] [Related]
24. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
Hanauske AR; Dumez H; Piccart M; Yilmaz E; Graefe T; Gil T; Simms L; Musib L; Awada A
Invest New Drugs; 2009 Aug; 27(4):356-65. PubMed ID: 18956139
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
26. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.
Zhang GZ; Jiao SC; Meng ZT
J Exp Clin Cancer Res; 2010 Apr; 29(1):38. PubMed ID: 20423465
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
[TBL] [Abstract][Full Text] [Related]
28. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients.
Ellis PM; Kaiser R; Zhao Y; Stopfer P; Gyorffy S; Hanna N
Clin Cancer Res; 2010 May; 16(10):2881-9. PubMed ID: 20460487
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
[TBL] [Abstract][Full Text] [Related]
30. Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.
Sakata S; Sasaki J; Saeki S; Hamada A; Kishi H; Nakamura K; Tanaka H; Notsute D; Sato R; Saruwatari K; Iriki T; Akaike K; Fujii S; Hirosako S; Kohrogi H
Oncology; 2015; 88(4):201-7. PubMed ID: 25502447
[TBL] [Abstract][Full Text] [Related]
31. A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors.
Chu QS; Sangha R; Hotte SJ; Sergenson G; Schnell D; Chand VK; Hirte HW
Invest New Drugs; 2014 Dec; 32(6):1226-35. PubMed ID: 25037863
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
33. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
[TBL] [Abstract][Full Text] [Related]
35. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
[TBL] [Abstract][Full Text] [Related]
37. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
Nishio M; Horai T; Horiike A; Nokihara H; Yamamoto N; Takahashi T; Murakami H; Yamamoto N; Koizumi F; Nishio K; Yusa W; Koyama N; Tamura T
Br J Cancer; 2013 Aug; 109(3):538-44. PubMed ID: 23860537
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
Ho C; Davies AM; Sangha RS; Lau D; Lara P; Chew HK; Beckett L; Mack PC; Riess JW; Gandara DR
Invest New Drugs; 2013 Dec; 31(6):1587-91. PubMed ID: 24013936
[TBL] [Abstract][Full Text] [Related]
39. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
Vansteenkiste J; Solomon B; Boyer M; Wolf J; Miller N; Di Scala L; Pylvaenaeinen I; Petrovic K; Dimitrijevic S; Anrys B; Laack E
J Thorac Oncol; 2011 Dec; 6(12):2120-9. PubMed ID: 21900840
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
